Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal sarcomas of the upper digestive tract.
Imatinib is the first-line therapy for patients with metastatic or unresectable GISTs.
However, the majority of GIST patients eventually develop imatinib resistance.
